Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 7707 results

  1. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued [GID-TA10922]

    Technology appraisal guidance
    Discontinued

  2. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued [GID-TA10857]

    Technology appraisal guidance
    Discontinued

  3. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued [GID-TA11210]

    Technology appraisal guidance
    Discontinued

  4. Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

    In development [GID-TA11126] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued [GID-TA11175]

    Technology appraisal guidance
    Discontinued

  7. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued [GID-TA10494]

    Technology appraisal guidance
    Discontinued

  8. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

    Technology appraisal guidance
    Discontinued

  10. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued [GID-TA10375]

    Technology appraisal guidance
    Discontinued

  11. PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

    Discontinued [GID-TA10402]

    Technology appraisal guidance
    Discontinued

  12. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued [GID-TA10689]

    Technology appraisal guidance
    Discontinued

  13. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued [GID-TA10397]

    Technology appraisal guidance
    Discontinued

  14. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued [GID-TA10686]

    Technology appraisal guidance
    Discontinued

  15. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued [GID-TA10687]

    Technology appraisal guidance
    Discontinued